To further validate the expression of EP300 in urological cancers, immunohistochemistry analysis showed that EP300 was significantly up-regulated in TGCT (100%, n = 12), kidney_tumor (100%, n = 11), BLCA (99%, n = 12) and PRAD (100%, n = 12) (Figures 3C, D). This evidence concerns the gene EP300 and neoplasm.